Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab

J Am Acad Dermatol. 2020 Jul;83(1):261-263. doi: 10.1016/j.jaad.2020.02.045. Epub 2020 Feb 21.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Clinical Trials as Topic
  • Dermatologic Agents / adverse effects*
  • Female
  • Humans
  • Interleukin-17 / antagonists & inhibitors
  • Interleukin-17 / immunology
  • Male
  • Middle Aged
  • Pharmacovigilance*
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Severity of Illness Index
  • Treatment Outcome
  • Urinary Tract Infections / chemically induced
  • Urinary Tract Infections / epidemiology*
  • Urinary Tract Infections / immunology
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • Interleukin-17
  • ixekizumab